ArticleRevista da Sociedade Brasileira de Medicina Tropical2026
Prevalence of SARS-CoV-2 Infection Among Vulnerable Populations Relying on Public Health Services: Findings from the AVISA Study in Brazil.
Article in Revista da Sociedade Brasileira de Medicina Tropical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Implementing a multi-centric cohort study during the SARS-CoV-2 pandemic in a resource-constrained setting: challenges, adaptive solutions, and lessons from Brazil.Archives of public health = Archives belges de sante publique · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding SARS-CoV-2 seroprevalence among vulnerable populations is crucial, especially in countries with universal but resource-constrained healthcare systems, such as Brazil.
methodsThis was a cross-sectional, population-based household survey within the AVISA study, which aimed to assess seroprevalence among households enrolled in the Family Health Program (ESF). Two serological assays (rapid test and ECLIA) were used to detect anti-SARS-CoV-2 antibodies. Descriptive statistics were calculated and survey-adjusted Poisson regression models with robust variance were estimated, yielding prevalence ratios (PRs) and 95% confidence intervals (CIs).
resultsThe overall weighted seroprevalence was 35.66% (95% CI: 30.55-40.77) in 2,986 participants. Compared with individuals in the Southeast region, participants in the Northeast and North regions had a 1.48- and 1.38-times higher prevalence of SARS-CoV-2 testing positivity, respectively. Relative to individuals who self-identified as having Black or Brown skin color using IBGE-defined categories, White had a 22% lower prevalence of seropositivity (PR = 0.78, 95% CI 0.63-0.97). Compared to those living in households with four to five family members, individuals living in households with six or more family members had a higher prevalence of seropositivity (PR = 1.34, 95% CI 1.05-1.71). Individuals in the lowest per capita household income quintile were more likely to have SARS-CoV-2 infection (PR = 1.89, 95% CI 1.21-2.95) than those in the highest.
conclusionThis study is the first to assess SARS-CoV-2 seroprevalence among ESF participants, a socioeconomically vulnerable population, served by the primary care public health system. Lower socioeconomic status was associated with higher seroprevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.